Bilingual Patient Education Manager - Spanish/English (Location Flexible) - Rhythm Pharmaceuticals
Tampa, FL
About the Job
Company Overview
Rhythm is a global, commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. We develop medicines for previously untreatable or undertreated diseases and provide meaningful support for healthcare providers and patients and their families. We recognize the courage it takes for patients and their caregivers to begin their journey of advocacy to find the answers they need. Their courage inspires us to challenge convention, ask bold questions and seek answers for them. Every day, we strive for excellence through our willingness to adapt, learn, and our tenacity to overcome barriers, together.
Opportunity Overview
As a Patient Education Manager, you will be a field-based member of the commercial team. Bilingual and fluent in Spanish and English, you will be responsible for supporting the patient-centric business model, responding to the needs of Spanish speaking patients and caregivers through engagement, education, care coordination and resolution of treatment access related barriers. You will establish strong relationships with people living with rare genetic diseases of obesity (RGDO) and their caregivers, serving as an integral resource throughout their journey. In this capacity, you will provide support and connect patients and health care providers to the resources they need, to optimize patient care, while working collaboratively within a team environment.
In this role, you will support Spanish-speaking patients and caregivers across multiple states, including Florida, Texas, Puerto Rico, New York and the coverage may adjust as our business and patients’ needs evolve.
Responsibilities and Duties
This role is field-based. Candidates applying must be willing and able to travel frequently and have easy access to transportation and airports.
More About Rhythm
Our lead asset, IMCIVREE® (setmelanotide), is a precision medicine designed to treat hyperphagia, an insatiable, pathological hunger characterized by abnormal food-seeking behaviors, and early- or rapid-onset severe obesity caused by an impairment of a pathway in the hypothalamus called the melanocortin-4 receptor (MC4R) pathway. IMCIVREE® is the first and only approved therapy for certain rare MC4R pathway diseases in the United States, Europe, Great Britain and several other countries. In collaboration with leading experts across the world, Rhythm is advancing the most comprehensive clinical research program ever initiated in MC4R pathway diseases, including a Phase 3 trial for acquired hypothalamic obesity. In addition, we are leveraging our extensive genetic database, global network of researchers, a track record of regulatory successes and global commercial infrastructure to develop a full portfolio of treatment options to patients struggling with hyperphagia and severe obesity and ensuring they get the treatment that is right for them.
We continue to advance care and precision medicines that address rare diseases. We are focused on expanding access to IMCIVREE® to reach more patients and developing novel therapies for other rare neuroendocrine diseases, including congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Rhythm is a global, commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. We develop medicines for previously untreatable or undertreated diseases and provide meaningful support for healthcare providers and patients and their families. We recognize the courage it takes for patients and their caregivers to begin their journey of advocacy to find the answers they need. Their courage inspires us to challenge convention, ask bold questions and seek answers for them. Every day, we strive for excellence through our willingness to adapt, learn, and our tenacity to overcome barriers, together.
Opportunity Overview
As a Patient Education Manager, you will be a field-based member of the commercial team. Bilingual and fluent in Spanish and English, you will be responsible for supporting the patient-centric business model, responding to the needs of Spanish speaking patients and caregivers through engagement, education, care coordination and resolution of treatment access related barriers. You will establish strong relationships with people living with rare genetic diseases of obesity (RGDO) and their caregivers, serving as an integral resource throughout their journey. In this capacity, you will provide support and connect patients and health care providers to the resources they need, to optimize patient care, while working collaboratively within a team environment.
In this role, you will support Spanish-speaking patients and caregivers across multiple states, including Florida, Texas, Puerto Rico, New York and the coverage may adjust as our business and patients’ needs evolve.
Responsibilities and Duties
- Deliver in-depth disease state and product education to support and empower patients/caregivers as they navigate treatment access
- Identify and resolve patient specific barriers and develops action plans for resolution to allow patients/caregivers to manage their disease and treatment as recommended by their healthcare provider
- Responsible for delivery of education programs (in person and virtual) to patients and families affected by RGDO
- Provide care coordination for patients/caregivers working as a liaison with the Field Access Manager and Territory Manager/ Sales to help facilitate the reimbursement and fulfillment process
- Effectively collaborate with cross functional partners to solve complex patient and customer issues
- Respond to all customer inquiries, provides appropriate education and support and triages to available resources
- Maintain comprehensive understanding of regional trends (payor and customer)
- Meet documentation requirements to facilitate tracking of critical metrics
- Ensure full compliance with all corporate and industry policies and legal and regulatory requirements for all regional commercial activities
- Bachelor’s degree and/or combination of work experience; nursing, social work, dietitian, or clinical background preferred
- 6 years of related experience, including supporting patients within Rare Disease
- Knowledge of insurance and payor landscape and US reimbursement process
- Prior product launch experience preferred
- Ability to work quickly and flexibly with resource constraints, exhibiting a results-drive mindset
- Ability to work both independently and collaboratively with a diverse team
- Ability to travel in the U.S. (up to 50% travel)
This role is field-based. Candidates applying must be willing and able to travel frequently and have easy access to transportation and airports.
More About Rhythm
Our lead asset, IMCIVREE® (setmelanotide), is a precision medicine designed to treat hyperphagia, an insatiable, pathological hunger characterized by abnormal food-seeking behaviors, and early- or rapid-onset severe obesity caused by an impairment of a pathway in the hypothalamus called the melanocortin-4 receptor (MC4R) pathway. IMCIVREE® is the first and only approved therapy for certain rare MC4R pathway diseases in the United States, Europe, Great Britain and several other countries. In collaboration with leading experts across the world, Rhythm is advancing the most comprehensive clinical research program ever initiated in MC4R pathway diseases, including a Phase 3 trial for acquired hypothalamic obesity. In addition, we are leveraging our extensive genetic database, global network of researchers, a track record of regulatory successes and global commercial infrastructure to develop a full portfolio of treatment options to patients struggling with hyperphagia and severe obesity and ensuring they get the treatment that is right for them.
We continue to advance care and precision medicines that address rare diseases. We are focused on expanding access to IMCIVREE® to reach more patients and developing novel therapies for other rare neuroendocrine diseases, including congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Powered by JazzHR
Source : Rhythm Pharmaceuticals